Ind-Swift posts Q4 FY24 consolidated PAT at Rs. 37.53 Cr

The company has posted net profit of Rs. 14.23 crores for the Financial Year ended March 31, 2024

IOL Chemicals and Pharmaceuticals posts Q4 FY24 consolidated PAT at Rs. 27.62 Cr

The company has posted net profit of Rs.134.43 crores for the Financial Year ended March 31, 2024

Thyrocare Technologies posts Q4 FY24 consolidated PAT at Rs. 17.78 Cr

The company has posted net profit of Rs.70.76 crores for the Financial Year ended March 31, 2024

Biocon signs supply deal with Medix for commercialization of generic Saxenda in Mexico

Lonza reports softer performance in Q1 2024

Outlook 2024 remains flat CER sales growth and CORE EBITDA margin of high 20s

Coveris invests over €8 million in production capacity

Investing considerably in production capacity for medical device packaging at its Rohrdorf and Halle sites in Germany

Sanofi India posts Q1 CY24 PAT at Rs. 136.6 Cr

Sanofi India has reported total income of Rs. 738.9 crores during the period ended March 31, 2024

Zydus receives final approval from USFDA for Dexamethasone Tablets

Dexamethasone Tablets USP, 1 mg had annual sales of US$ 1.8 mn in the United States (IQVIA MAT March 24)

Briefs: Lupin and Aurobindo Pharma

Lupin updates on shipment of Mirabegron ER Tablets

Novartis India posts Q4 FY24 net profit lower at Rs. 14.68 Cr

Novartis India has reported total income of Rs. 91.59 crores during the period ended March 31, 2024